Professional Documents
Culture Documents
DIABETES TIPO 1
Menos de un tercio de los pacientes con diabetes tipo 1 logra un control glucémico
óptimo (hemoglobina glicosilada [HbA1c], 7%).
Incluso cuando se alcanzan los niveles objetivo de HbA1c, todavía hay evidencia de
un exceso de mortalidad en pacientes con diabetes tipo 1
La terapia con insulina es la base del tratamiento; sin embargo, se asocia con
hipoglucemia y aumento de peso, ambos son importantes factores de riesgo
cardiovascular
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
INTRODUCCIÓN:
INHIBIDORES DEL COTRANSPORTADOR
SODIO-GLUCOSA TIPO 2 (SGLT2)
DAPAGLIFOZINA SOTAGLIFLOZINA
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
MATERIALES Y MÉTODOS:
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
PARTICIPANTES DEL ESTUDIO
CRITERIOS DE INCLUSION
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
PARTICIPANTES DEL ESTUDIO
• Diabetes tipo 2 / Diabetes MODY
• Historia de cirugía pancreática
• Pancreatitis crónica
• Trastornos pancreáticos que resultan en una
disminución de la capacidad de las células beta, signos
de diabetes mal controlada (incluida la Cetoacidosis
Diabética que requiere intervención médica u
hospitalización por hiperglucemia o hipoglucemia en el
CRITERIOS DE EXCLUSION
transcurso de 1 mes antes del screening)
• Enfermedad cardiovascular (dentro de los 6 meses
previos al screening)
• Enfermedad renal que progresa rápidamente
• Enfermedad hepática significativa
• Malignidad (dentro de los 5 años previos)
• Uso previo de cualquier inhibidor del SGLT2
• Tomar metformina y / o tiazolidinedionas durante los 2
meses anteriores al screening
• Tomar cualquier agente antihiperglicemico que no sea
insulina durante 1 mes antes del examen
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
PROCEDIMIENTO Y MEDICACIÓN EN EL ESTUDIO
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
Variación en la HbA1c a las 24 semanas del tratamiento
doble ciego con dapagliflozina 5 mg o dapagliflozina 10 mg
PRIMARIO
más insulina titulable versus placebo más insulina titulable.
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
SEGURIDAD Y TOLERABILIDAD
EVENTOS ADVERSOS (AE) y eventos adversos graves (SAEs), signos vitales,
hallazgos del examen físico, electrocardiograma y valores de laboratorio, y
lecturas domiciliarias de BOHB.
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
TAMAÑO Y POTENCIA DE MUESTRA
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
Inicial: 8/07/2015 – 2/10/2017
Final: 18/04/18
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
537
276
258
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
FIGURA 2A
Cambios en la
HbA1C
DAPA: Dapaglifozina
INS: Insulina
PBO: Placebo
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
SI CGM personal
No CGM personal
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
FIGURA 2B
Cambios en la
dosis diaria total
de insulina (TDD)
DAPA: Dapaglifozina
INS: Insulina
PBO: Placebo
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
Cambio en el
valor medio de
las lecturas de
glucosa de 24
horas
Cambios en el
MAGE
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
Cambios en el
porcentaje de
lecturas de
glucosa de 24
horas dentro del
rango objetivo de
> 70 a <= 180
mg/dL )
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
FIGURA 2C
Cambio
porcentual en el
peso corporal
(BW)
DAPA: Dapaglifozina
INS: Insulina
PBO: Placebo
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
FIGURA 2D
Proporción de
pacientes que
lograron una
disminución de
HbA1c de >=
0.5% sin
hipoglicemia
severa
INS: Insulina
PBO: Placebo
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
RESULTADOS
DEPICT-2 es el segundo de dos estudios aleatorizados, doble ciego, de fase 3 que evalúan
la eficacia y seguridad de dapagliflozina como terapia adjunta a la insulina titulada en
pacientes adultos con diabetes tipo 1 controlada inadecuadamente .
El diseño del estudio es el mismo que el del estudio DEPICT-1 de 24 semanas. Sin
embargo, existen algunas diferencias entre los estudios, como menos visitas al sitio en el
estudio DEPICT-2 y la huella geográfica de DEPICT-2, que incluyó pacientes de América
del Norte, América Latina, Europa y Japón (con un 19,7% de pacientes japoneses).
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
CONCLUSIONES
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
CONCLUSIONES
Los beneficios del uso de inhibidores de SGLT2 en el tratamiento de la diabetes tipo 1
deben equilibrarse con el mayor riesgo de CDA. La incidencia de eventos definitivos
de CDA en DEPICT-2 fue mayor en comparación con DEPICT-1 (dapagliflozina 5 mg
frente a dapagliflozina 10 mg frente a placebo: 5,83, 4,99 y 0 por 100 pacientes-año
en DEPICT-2, respectivamente; 3,29; 3.78 y 2.64 por 100 paciente-años en DEPICT-1)
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
CONCLUSIONES
Tomados en conjunto, los estudios DEPICT brindan evidencia sólida a corto plazo
para la dapagliflozina como un candidato adecuado para su uso como terapia
adjunta a la insulina para mejorar el control glucémico en pacientes con diabetes
tipo 1.
Mathieu C, Dandona P, Gillard P, et.al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type
1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018
Sep;41(9):1938-1946
GRACIAS